This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Sep 12;381(11):1089.

doi: 10.1056/NEJMc1909687.

Canagliflozin and Renal Outcomes in Diabetic Nephropathy

Adrian Post¹, Michele F Eisenga¹, Stephan J L Bakker¹

Affiliations

PMID: 31509684
DOI: 10.1056/NEJMc1909687

Comment

Canagliflozin and Renal Outcomes in Diabetic Nephropathy

Adrian Post et al. N Engl J Med. 2019.

. 2019 Sep 12;381(11):1089.

doi: 10.1056/NEJMc1909687.

Authors

Adrian Post¹, Michele F Eisenga¹, Stephan J L Bakker¹

Affiliation

¹ University Medical Center Groningen, Groningen, the Netherlands a.post01@umcg.nl.

PMID: 31509684
DOI: 10.1056/NEJMc1909687

No abstract available

PubMed Disclaimer

Comment in

Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply.
Jardine MJ, Mahaffey KW, Perkovic V. Jardine MJ, et al. N Engl J Med. 2019 Sep 12;381(11):1089-1090. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509685 No abstract available.

Comment on

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Clinical Trial.

Similar articles

Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Lima JG, Santos MC, Simas BC. Lima JG, et al. N Engl J Med. 2019 Sep 12;381(11):1088-1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509683 No abstract available.
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Isreb M, Al-Makki A, Buatois E. Isreb M, et al. N Engl J Med. 2019 Sep 12;381(11):1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509682 No abstract available.
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Leslie BR, Gerwin LE. Leslie BR, et al. N Engl J Med. 2019 Sep 12;381(11):1087-1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509681 No abstract available.
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C. Wanner C. Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8. Nat Rev Nephrol. 2018. PMID: 29307892 Review. No abstract available.
Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A. Mima A. J Diabetes Complications. 2018 Jul;32(7):720-725. doi: 10.1016/j.jdiacomp.2018.04.011. Epub 2018 May 5. J Diabetes Complications. 2018. PMID: 29880432 Review.

See all similar articles

Cited by

Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
Post A, Groothof D, Eisenga MF, Bakker SJL. Post A, et al. J Clin Med. 2020 May 25;9(5):1603. doi: 10.3390/jcm9051603. J Clin Med. 2020. PMID: 32466262 Free PMC article.
Ertugliflozin, renoprotection and potential confounding by muscle wasting.
Groothof D, Post A, Gans ROB, Bakker SJL. Groothof D, et al. Diabetologia. 2022 May;65(5):906-907. doi: 10.1007/s00125-021-05614-0. Epub 2021 Dec 23. Diabetologia. 2022. PMID: 34940888 No abstract available.
Oat β Glucan Ameliorates Renal Function and Gut Microbiota in Diabetic Rats.
Wang R, Zhang Z, Aihemaitijiang S, Ye C, Halimulati M, Huang X, Qin H. Wang R, et al. Front Nutr. 2022 May 9;9:875060. doi: 10.3389/fnut.2022.875060. eCollection 2022. Front Nutr. 2022. PMID: 35614982 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information